{"record_key":"peptilogics","identifier":"peptilogics","external_key":"B77D55","title":"Peptilogics","summary":null,"url":"https://inventions.pitt.edu/startups/peptilogics","json_url":"https://inventions.pitt.edu/startups/peptilogics.json","object_key":"startups","description":"Peptilogics is developing engineered peptide medicines to address difficult medical device-related bacterial infections. Its lead investigational candidate, zaloganan (PLG0206), targets bacterial biofilms, with an initial focus on infections involving prosthetic joints. The Pittsburgh company was founded by Jonathan Steckbeck. [1]: https://peptilogics.com/company/ [2]: https://peptilogics.com/pipeline/\nIn March 2026, Peptilogics began enrolling patients in RETAIN, a randomized Phase 2/3 trial evaluating PLG0206 during surgery for infections following total knee replacement. A $78 million Series B2 financing announced in October 2025 supports pivotal development of the program. [3]: https://peptilogics.com/news/peptilogics-begins-pivotal-trial-of-first-ever-drug-designed-to-cure-medical-device-related-infections/ [4]: https://peptilogics.com/news/peptilogics-raises-78-million-to-advance-zaloganan-into-pivotal-trial/","attributes":[{"key":"website","label":"Website","values":["https://peptilogics.com/"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Musculoskeletal"]},{"key":"funding_stage","label":"Funding Stage","values":["Series A+"]},{"key":"founders","label":"Founders","values":["Jonathan Steckbeck"]}],"related":[]}